📣 VC round data is live. Check it out!
Bliss GVS Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bliss GVS Pharma
Bliss GVS Pharma Overview
About Bliss GVS Pharma
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from Exports.
Founded
1984
HQ
Employees
966
Website
Financials (FY)
EV
$447M
Valuation Multiples
Start free trial
Bliss GVS Pharma Financials
Bliss GVS Pharma reported last fiscal year revenue of $97M and EBITDA of $24M.
In the same fiscal year, Bliss GVS Pharma generated $52M in gross profit, $24M in EBITDA, and $13M in net income.
Bliss GVS Pharma P&L
In the most recent fiscal year, Bliss GVS Pharma reported revenue of $97M and EBITDA of $24M.
Bliss GVS Pharma is profitable as of last fiscal year, with gross margin of 54%, EBITDA margin of 25%, and net margin of 14%.
Financial data powered by Morningstar, Inc.
Bliss GVS Pharma Stock Performance
Bliss GVS Pharma has current market cap of $468M, and enterprise value of $447M.
Bliss GVS Pharma's stock price is $4.42.
Bliss GVS Pharma has an EPS (earnings per share) of $0.13.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $447M | $468M | 7.2% | - | - | - | $0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBliss GVS Pharma Valuation Multiples
Bliss GVS Pharma trades at 4.6x EV/Revenue multiple, and 18.2x EV/EBITDA.
Bliss GVS Pharma Financial Valuation Multiples
As of May 30, 2026, Bliss GVS Pharma has market cap of $468M and EV of $447M.
Bliss GVS Pharma has a P/E ratio of 34.8x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bliss GVS Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bliss GVS Pharma Margins & Growth Rates
In the most recent fiscal year, Bliss GVS Pharma reported gross margin of 54%, EBITDA margin of 25%, and net margin of 14%.
Bliss GVS Pharma Margins
Bliss GVS Pharma Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Bliss GVS Pharma Operational KPIs
Bliss GVS Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Bliss GVS Pharma's Rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bliss GVS Pharma's Rule of X is 34% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Bliss GVS Pharma Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Bliss GVS Pharma competitors and their valuation data. Start Free Trial | ||||||
Bliss GVS Pharma Funding History
Before going public, Bliss GVS Pharma raised $144M in total equity funding, across 1 round.
Last private valuation of Bliss GVS Pharma was $14M, after raising $144M in May 2026 from Anupam Rasayan India.
Bliss GVS Pharma Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bliss GVS Pharma
| When was Bliss GVS Pharma founded? | Bliss GVS Pharma was founded in 1984. |
| Where is Bliss GVS Pharma headquartered? | Bliss GVS Pharma is headquartered in India. |
| How many employees does Bliss GVS Pharma have? | As of today, Bliss GVS Pharma has over 966 employees. |
| Is Bliss GVS Pharma publicly listed? | Yes, Bliss GVS Pharma is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Bliss GVS Pharma? | Bliss GVS Pharma trades under BLISSGVS ticker. |
| When did Bliss GVS Pharma go public? | Bliss GVS Pharma went public in 2010. |
| Who are competitors of Bliss GVS Pharma? | Bliss GVS Pharma main competitors include |
| What is the current market cap of Bliss GVS Pharma? | Bliss GVS Pharma's current market cap is $468M. |
| What is the current revenue of Bliss GVS Pharma? | Bliss GVS Pharma's last fiscal year revenue is $97M. |
| What is the current EV/Revenue multiple of Bliss GVS Pharma? | Current revenue multiple of Bliss GVS Pharma is 4.6x. |
| Is Bliss GVS Pharma profitable? | No, Bliss GVS Pharma is not profitable. |
| How many companies Bliss GVS Pharma has acquired to date? | Bliss GVS Pharma hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Bliss GVS Pharma has invested to date? | Bliss GVS Pharma hasn't invested in any companies yet (or none have been disclosed publicly). |
Lists including Bliss GVS Pharma
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.